Details of the Drug Combinations

General Information of This Drug (ID: DMFU0JY)

• Drug Name: TH-302 (DMFU0JY)
• Synonyms: TH-302; evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; TH-302; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174

Indication

Soft tissue sarcoma; ICD 11: 2B57; Status: Phase 2 [1]; Melanoma; ICD 11: 2C30; Status: Phase 1 [2]; Pancreatic cancer; ICD 11: 2C10; Status: Phase 1 [2]; Prostate cancer; ICD 11: 2C82.0; Status: Phase 1 [2]; Squamous cell carcinoma; ICD 11: 2B60-2D01; Status: Phase 1 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
TH-302 + Panobinostat	DCT83E1	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
TH-302 + Marizomib	DCMR1KO	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Gemcitabine + TH-302	DC5OPE8	Gemcitabine	Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma	[4]
Gemcitabine + TH-302	DCVBI4G	Gemcitabine	Solid Tumor	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8695).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT01746979) Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
• [5] ClinicalTrials.gov (NCT01833546) A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer